Press-release for stocks for NTRA

| -8.29% | O: -0.13% H: 0.69% C: 0.14%
LH M | $207.97 2.41% 0.0% 930K

| -15.47% | O: -0.38% H: 0.3% C: -0.87%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 142.26% | O: -0.82% H: 1.64% C: 0.64%
MYGN | $18.595 0.57% 0.56% 510K

| -5.3% | O: -1.63% H: 2.02% C: -2.43%
ILMN | $124.41 3.46% 3.34% 1.3M

| -43.17% | O: -0.76% H: 1.23% C: -0.19%
genetic expected market

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
Published: 2022-11-23 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 157.03% | O: 0.17% H: 7.02% C: 4.93%
conference

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
Published: 2022-11-21 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 155.59% | O: -0.79% H: 2.91% C: -0.14%
melanoma immunotherapy technology response study

Natera Announces Pricing of Follow-On Offering - November 16, 2022
Published: 2022-11-16 (Crawled : 08:00) - biospace.com/
MS | News | $93.76 1.81% 0.12% 6.4M

| 3.6% | O: -0.03% H: 0.0% C: -0.72%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 166.43% | O: 7.29% H: 8.18% C: 0.19%
offering

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China Kinarus Therapeutics Holding AG announced that it has engaged Great Health Companion Group Ltd, a subsidiary o...
Published: 2022-11-16 (Crawled : 08:00) - biospace.com/
A | $139.2 3.95% -0.14% 2M

| -5.95% | O: 0.13% H: 0.38% C: -0.72%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 166.43% | O: 7.29% H: 8.18% C: 0.19%
health therapeutics china group

Natera Announces Pricing of Follow-On Offering
Published: 2022-11-16 (Crawled : 05:00) - prnewswire.com
MS | News | $93.76 1.81% 0.12% 6.4M

| 3.6% | O: -0.03% H: 0.0% C: -0.72%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 166.43% | O: 7.29% H: 8.18% C: 0.19%
offering

Natera Launches Proposed Follow-On Offering - November 15, 2022
Published: 2022-11-15 (Crawled : 01:00) - biospace.com/
MS | News | $93.76 1.81% 0.12% 6.4M

| 4.4% | O: 1.4% H: 0.87% C: -0.63%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 156.74% | O: 2.06% H: 2.18% C: -5.58%
offering

Global Liquid Biopsy Market Report 2022: Increased Awareness Regarding Cancer Boosts 13.77% Annual Growth
Published: 2022-11-08 (Crawled : 21:00) - prnewswire.com
BIO | $285.28 1.84% 0.0% 230K

| -25.29% | O: -0.44% H: 6.91% C: 6.14%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 114.51% | O: 3.06% H: 0.43% C: -15.25%
MYGN | $18.595 0.57% 0.56% 510K

| 3.33% | O: -0.78% H: 5.43% C: 3.08%
ILMN | $124.41 3.46% 3.34% 1.3M

| -42.92% | O: -1.08% H: 1.4% C: 0.07%
BIOC | $0.4349 -10.32% 750K

| -45.63% | O: -1.24% H: 3.8% C: -6.33%
global report cancer growth market

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs
Published: 2022-11-02 (Crawled : 13:00) - prnewswire.com
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 95.07% | O: -0.41% H: 2.73% C: -2.22%
contract

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference
Published: 2022-11-01 (Crawled : 20:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 93.87% | O: 1.41% H: 1.07% C: -1.99%
conference

Natera to Report its Third Quarter 2022 Results on November 8th
Published: 2022-11-01 (Crawled : 13:20) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 93.87% | O: 1.41% H: 1.07% C: -1.99%
report results

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Published: 2022-10-06 (Crawled : 13:20) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 95.2% | O: 0.45% H: 1.75% C: 0.38%
test cancer publication ovarian cancer

Natera Announces 2025 ESG Goals with Publication of 2021 Report
Published: 2022-09-29 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 97.7% | O: -1.32% H: 0.61% C: -2.13%
report esg publication

Non Invasive Prenatal Testing Market Worth $7.71 Billion by 2030 - Grand View Research, Inc.
Published: 2022-09-14 (Crawled : 14:00) - prnewswire.com
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 80.1% | O: 0.59% H: 1.08% C: -2.89%
ILMN | $124.41 3.46% 3.34% 1.3M

| -37.49% | O: -0.08% H: 0.62% C: -1.06%
CNTG | $0.504 7.21% 6.73% 72K

Commercial Services

| -67.57% | O: 0.0% H: 0.0% C: -2.03%
market

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Published: 2022-09-12 (Crawled : 15:20) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 72.03% | O: 1.25% H: 0.0% C: -0.5%
treatment cancer

Natera to Participate in Upcoming Investor Conferences
Published: 2022-09-06 (Crawled : 18:00) - prnewswire.com
MS | News | $93.76 1.81% 0.12% 6.4M

| 8.52% | O: 0.41% H: 0.1% C: -1.87%
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 91.06% | O: 0.67% H: 1.23% C: -0.48%

Natera Earns Great Place to Work Certification™ for Second Consecutive Year
Published: 2022-08-25 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 74.88% | O: 2.54% H: 0.13% C: -1.16%
work year

Natera Announces Enrollment Completion for RenaCARE Study
Published: 2022-08-11 (Crawled : 12:00) - prnewswire.com
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 64.66% | O: 0.0% H: 4.68% C: -3.07%
study

Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
Published: 2022-08-10 (Crawled : 23:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M

| 79.14% | O: 3.29% H: 6.84% C: 5.33%
panorama fda

Natera Reports Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 00:00) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M